PMID- 30705951
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2364-3722 (Print)
IS  - 2196-9736 (Electronic)
IS  - 2196-9736 (Linking)
VI  - 7
IP  - 2
DP  - 2019 Feb
TI  - Alcohol-free EUS-guided chemoablation of multiple pancreatic insulinomas.
PG  - E186-E188
LID - 10.1055/a-0764-4736 [doi]
AB  - Background and study aims  Endoscopic ultrasound (EUS)-guided chemoablation with 
      ethanol lavage, followed by infusion with paclitaxel, has been found to be 
      effective for treatment of mucinous pancreatic cysts. However, there are notable 
      adverse events (AEs) associated with ethanol and its undesirable inflammatory 
      effects on local tissue and vessels. The recent ChARM trial demonstrated that 
      removing ethanol from the cyst ablation process resulted in equivalent efficacy 
      while significantly reducing associated AEs. Encouraged by these results, we 
      speculated that alcohol-free chemoablation can be applied to treatment of solid 
      tumors, as described in our case with a patient with severe and symptomatic 
      recurrent hypoglycemia in the setting of multifocal insulinomas. As a result, the 
      patient saw a significant reduction in symptoms. EUS-guided alcohol-free 
      chemoablation may represent a new alternative to previously established therapies 
      that will ultimately reduce risk of AEs.
FAU - Gaballa, Daniel
AU  - Gaballa D
AD  - Department of Internal Medicine, Division of Gastroenterology, Penn State 
      University Hospital, Hershey Medical Center, Hershey, Pennsylvania, United 
      States.
FAU - Abendroth, Catherine S
AU  - Abendroth CS
AD  - Department of Pathology, Division of Anatomic Pathology, Penn State University 
      Hospital, Hershey Medical Center, Hershey, Pennsylvania, United States.
FAU - Moyer, Matthew T
AU  - Moyer MT
AD  - Department of Internal Medicine, Division of Gastroenterology, Penn State 
      University Hospital, Hershey Medical Center, Hershey, Pennsylvania, United 
      States.
LA  - eng
PT  - Case Reports
DEP - 20190118
PL  - Germany
TA  - Endosc Int Open
JT  - Endoscopy international open
JID - 101639919
PMC - PMC6338548
COIS- Competing interests Dr. Moyer is a consultant for Boston Scientific.
EDAT- 2019/02/02 06:00
MHDA- 2019/02/02 06:01
PMCR- 2019/02/01
CRDT- 2019/02/02 06:00
PHST- 2018/02/13 00:00 [received]
PHST- 2018/06/25 00:00 [accepted]
PHST- 2019/02/02 06:00 [entrez]
PHST- 2019/02/02 06:00 [pubmed]
PHST- 2019/02/02 06:01 [medline]
PHST- 2019/02/01 00:00 [pmc-release]
AID - 10.1055/a-0764-4736 [doi]
PST - ppublish
SO  - Endosc Int Open. 2019 Feb;7(2):E186-E188. doi: 10.1055/a-0764-4736. Epub 2019 Jan 
      18.